During the forecast period 2023 to 2033, the Panuveitis Treatment Market is expected to grow at a value of 9.5% CAGR, according to Future Market Insights. By the year 2033, the global market for panuveitis treatment is expected to rise up to a market valuation of US$ 8.9 billion. Growth of the market can be attributed to increasing incidence of uveitis and related diseases, such as rheumatoid arthritis and Behcet's disease, and the growing demand for effective Panuveitis treatments.

There are several treatment options available for Panuveitis, including corticosteroids, immunosuppressants, biologics, and other anti-inflammatory drugs. The choice of treatment depends on the severity and underlying cause of the disease, as well as the patient's overall health and medical history.

North America is expected to dominate the global Panuveitis treatment market due to the high prevalence of uveitis and related diseases in the region. Europe is expected to be the second-largest market for Panuveitis treatment, owing to the increasing prevalence of autoimmune diseases in the region. Asia-Pacific is also expected to show significant growth, due to the large patient population, rising healthcare expenditure, and increasing awareness about the disease.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16870

Key Takeaways from the Market Study:

  • The global panuveitis treatment market is expected to grow with a 9.5% CAGR during 2023 to 2033.
  • By distribution channel, hospital pharmacies are expected to hold 49% of the market share in 2023 for Panuveitis treatment market.
  • North America is expected to possess 45% market share for Panuveitis treatment market in 2023.
  • Europe Panuveitis treatment market size is expected to possess 36% market share in 2023.

“Investment in research and development by key players along with development of innovative therapies is driving the growth of the market,” states an FMI analyst.

Competitive Landscape:

Key players in the Panuveitis treatment Market are Allergan, Inc., Novartis AG, Bausch Health Inc., AbbVie Inc., Tarsier Pharma, EyeGate Pharmaceuticals, Inc., Alimera Science Inc., Eyepoint Pharmaceutical, Santen Pharmaceutical

  • Allergan, Inc. has developed a drug called Ozurdex (dexamethasone intravitreal implant) for the treatment of non-infectious posterior segment uveitis, which includes panuveitis. Ozurdex is a sustained-release implant that delivers a potent corticosteroid (dexamethasone) directly into the eye, where it reduces inflammation and swelling.
  • Novartis AG has developed a drug called Ilaris (canakinumab) for the treatment of various inflammatory disorders, including certain forms of uveitis, including panuveitis. Ilaris is a monoclonal antibody that selectively binds to a pro-inflammatory protein called interleukin-1 beta (IL-1β), which is involved in the development of inflammation.

Key Segments Profiled in the Panuveitis Treatment Industry Survey

Drug Class:

  • Anti-inflammatory
  • Antimicrobial Drugs
  • Immunotherapy & Targeted Therapies

Route of Administration:

  • Oral
  • Topical

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa